Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADIPOR2 | Q86V24 | 1/20 | 0.81 |
| ▸ | ADIPOR1 | Q96A54 | 1/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24514569 | 0.93 | ADIPOR2 (0.70) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL25568932 | 0.92 | ADIPOR2 (0.77) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL4170598 | 0.91 | ADIPOR2 (0.67) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL4031641 | 0.90 | POLB (0.70) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL17946118 | 0.90 | ADIPOR2 (0.88) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL17938602 | 0.90 | ADIPOR2 (1.00) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL2210339 | 0.89 | ADIPOR2 (0.63) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL17950923 | 0.89 | ADIPOR2 (0.63) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL4036078 | 0.88 | POLB (0.65) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 | |
| SCHEMBL4161579 | 0.87 | SIGMAR1 (0.70) | ADIPOR2ADIPOR1POLBSIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234923-A1 | USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES | TRUSTEES OF TUFTS COLLEGE | 2023-07-27 | — | — | US | disclosed |
| US-11655212-B2 | Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes | TRUSTEES OF TUFTS COLLEGE (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220185777-A1 | USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES | TRUSTEES OF TUFTS COLLEGE | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655212-B2 | Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes | ADIPOR1, ADIPOR2, GPR119 | ADIPOR2 2/4885ADIPOR1 1/4885POLB 3985/4885 |
| US-20230234923-A1 | USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES | ADIPOR1, ADIPOR2, GPR119 | ADIPOR2 2/4885ADIPOR1 1/4885POLB 3985/4885 |
| US-20220185777-A1 | USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES | ADIPOR1, ADIPOR2, GPR119 | ADIPOR2 2/4885ADIPOR1 1/4885POLB 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.